TLSI Earnings Date: Nov 10, 2026 (Estimated) — TriSalus Life Sciences, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is TLSI's next earnings date?
TriSalus Life Sciences, Inc. (TLSI) is expected to report Q3 2026 earnings on Tuesday, November 10, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14 on revenue of $14.0M.
How did TLSI do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), TriSalus Life Sciences, Inc. posted EPS of -$0.16 versus the -$0.15 estimate, a miss of 45.5%. Revenue was $11.4M against a $10.3M estimate. The stock's 1-day post-earnings move was +15.2%.
How much does TLSI stock move after earnings?
TLSI beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.0% (up or down) in the day after earnings.
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.15 | -0.16 | -45.45% | $11.4M | ❌ Miss | +15.20% | +15.61% | +2.67% |
| 2026-05-12 | Q1 2026 | -0.16 | 0.03 | +118.75% | $8.9M | ✅ Beat | -41.45% | -30.92% | -20.18% |
| 2026-03-05 | Q4 2025 | -0.13 | -0.21 | -61.54% | $13.2M | ❌ Miss | -6.39% | -14.05% | -14.47% |
| 2025-11-13 | Q3 2025 | -0.17 | -0.96 | -464.71% | $11.6M | ❌ Miss | +3.87% | +12.98% | +66.51% |
| 2025-08-12 | Q2 2025 | -0.22 | -0.27 | -22.73% | $11.2M | ❌ Miss | +8.22% | +27.40% | +28.22% |
| 2025-03-27 | Q4 2024 | -0.35 | -0.40 | -14.29% | $8.3M | ❌ Miss | -1.43% | -0.90% | +2.69% |
| 2024-11-14 | Q3 2024 | -0.37 | -0.12 | +67.57% | $7.3M | ✅ Beat | -10.89% | -9.56% | -13.11% |
| 2024-08-14 | Q2 2024 | -0.49 | -0.21 | +57.14% | $7.4M | ✅ Beat | +0.64% | -5.34% | -22.77% |
Showing last 8 quarters.